Are we ready? Lessons from our recent payer and industry studies.
Watch our recording to discover how pharmaceutical companies are preparing for the EU Joint Clinical Assessment (JCA) implementation and understand how this regulation will shape the EU pharma landscape, impacting all key elements of the strategic P&MA tradeoff triangle: price, access, time-to-market.
Based on studies covering the viewpoints of both pharmaceutical companies as well as European payers, this webinar recording will provide first-hand key insights into the readiness of stakeholders across the industry to implement the EU JCA regulation.
This recording will cover:
- Preparation Insights: Find out how pharmaceutical companies are gearing up for the EU JCA—from updating internal processes to integrating JCA requirements into market access and evidence development strategies.
- Payer Perspectives: Discover how payers are planning to collaborate with regulators, EU JCA stakeholders, and pharmaceutical companies to minimize impact on patient access.
- Market Access Impact: Explore the short- and long-term implications of the EU JCA on market access, and understand the opportunities and challenges ahead for regulators, pharmaceutical companies, payers, physicians, and patients.
- Best Practices for Success: Discover proven strategies and best practices for navigating JCA implementation, ensuring your organization is well-prepared for the new regulation.
